Warfarin pharmacogenetics.

doi:10.1016/j.tcm.2014.09.001

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Warfarin pharmacogenetics.

Trends in cardiovascular medicine - 1 Jan 2015

Johnson Julie A, Cavallari Larisa H

Abstract excerpt

The cytochrome P450 (CYP) 2C9 and vitamin K epoxide reductase complex 1 (VKORC1) genotypes have been strongly and consistently associated with warfarin dose requirements, and dosing algorithms incorporating genetic and clinical information have been shown to be predictive of stable warfarin dose. However, clinical trials evaluating genotype-guided warfarin dosing produced mixed results, calling into question the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Cytochrome P-450 CYP2C9
Share to VKORC1 gene
Share to Genotype
Share to Pharmacogenetics
Share to Pharmacogenetics and Drug Metabolism
Share to Vitamin K Epoxide Reductases
Share to Warfarin

Source

Open in PubMed Open full text

Identifiers

PMID: 25282448
DOI: 10.1016/j.tcm.2014.09.001
PMCID: PMC4278947

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics